CHO Plus was founded in 2014 to address the high costs and capacity issues facing therapeutic protein manufacturers. We are developing cutting-edge Technologies for creating high-productivity GMP-compliant mammalian cell lines to be used for the manufacture of therapeutic proteins.
Our plan is to license our Technology to, and collect royalties from, biopharmaceutical companies that will manufacture their own protein products. Two patent applications have been filed covering our cell engineering and genome transcription hotspot Technologies. We are working with attorneys at Kilpatrick Townsend for intellectual property and general business needs.
CHO Plus was founded to address the high costs and production capacity limitations faced by therapeutic protein manufacturers. Our Technologies for creating and improving cell lines will lead to vastly higher-productivity processes while cutting costs associated with manufacturing and building expensive new plants. Our cell lines will be accepted by regulatory agencies and they will provide better performance (higher productivity) at a cost similar to accepted industry standards.